BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36637229)

  • 1. Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial.
    Green JE; Berk M; Mohebbi M; Loughman A; McGuinness AJ; Castle D; Chatterton ML; Perez J; Strandwitz P; Athan E; Hair C; Nierenberg AA; Cryan JF; Jacka F
    Can J Psychiatry; 2023 May; 68(5):315-326. PubMed ID: 36637229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and feasibility of faecal microbiota transplant for major depressive disorder: study protocol for a pilot randomised controlled trial.
    Green JE; McGuinness AJ; Berk M; Castle D; Athan E; Hair C; Strandwitz P; Loughman A; Nierenberg AA; Cryan JF; Mohebbi M; Jacka F
    Pilot Feasibility Stud; 2023 Jan; 9(1):5. PubMed ID: 36624505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.
    Halkjær SI; Christensen AH; Lo BZS; Browne PD; Günther S; Hansen LH; Petersen AM
    Gut; 2018 Dec; 67(12):2107-2115. PubMed ID: 29980607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn's disease population: PediCRaFT Trial.
    Pai N; Popov J; Hill L; Hartung E
    BMJ Open; 2019 Nov; 9(11):e030120. PubMed ID: 31784432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study.
    Jitsumura M; Cunningham AL; Hitchings MD; Islam S; Davies AP; Row PE; Riddell AD; Kinross J; Wilkinson TS; Jenkins GJ; Williams JG; Harris DA
    BMJ Open; 2018 Oct; 8(10):e021987. PubMed ID: 30341117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
    Johnsen PH; Hilpüsch F; Cavanagh JP; Leikanger IS; Kolstad C; Valle PC; Goll R
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and feasibility of faecal microbiota transplantation for patients with Parkinson's disease: a protocol for a self-controlled interventional donor-FMT pilot study.
    Vendrik KE; Chernova VO; Kuijper EJ; Terveer EM; van Hilten JJ; Contarino MF;
    BMJ Open; 2023 Oct; 13(10):e071766. PubMed ID: 37798034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis.
    Quraishi MNN; Yalchin M; Blackwell C; Segal J; Sharma N; Hawkey P; McCune V; Hart AL; Gaya D; Ives NJ; Magill L; Loi S; Hewitt C; Gerasimidis K; Loman NJ; Hansen R; McMullan C; Mathers J; Quince C; Crees N; Iqbal T
    BMJ Open; 2019 Nov; 9(11):e030659. PubMed ID: 31719078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal transplantation for treatment of inflammatory bowel disease.
    Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial.
    Yu EW; Gao L; Stastka P; Cheney MC; Mahabamunuge J; Torres Soto M; Ford CB; Bryant JA; Henn MR; Hohmann EL
    PLoS Med; 2020 Mar; 17(3):e1003051. PubMed ID: 32150549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.
    El-Salhy M; Hatlebakk JG; Gilja OH; Bråthen Kristoffersen A; Hausken T
    Gut; 2020 May; 69(5):859-867. PubMed ID: 31852769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial.
    Costello SP; Hughes PA; Waters O; Bryant RV; Vincent AD; Blatchford P; Katsikeros R; Makanyanga J; Campaniello MA; Mavrangelos C; Rosewarne CP; Bickley C; Peters C; Schoeman MN; Conlon MA; Roberts-Thomson IC; Andrews JM
    JAMA; 2019 Jan; 321(2):156-164. PubMed ID: 30644982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis.
    Halkjær SI; Lo B; Cold F; Højer Christensen A; Holster S; König J; Brummer RJ; Aroniadis OC; Lahtinen P; Holvoet T; Gluud LL; Petersen AM
    World J Gastroenterol; 2023 May; 29(20):3185-3202. PubMed ID: 37346153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than
    Green JE; Davis JA; Berk M; Hair C; Loughman A; Castle D; Athan E; Nierenberg AA; Cryan JF; Jacka F; Marx W
    Gut Microbes; 2020 Nov; 12(1):1-25. PubMed ID: 33345703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial.
    Pai N; Popov J
    BMJ Open; 2017 Aug; 7(8):e016698. PubMed ID: 28827258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blinded, placebo-controlled pilot study: efficacy of faecal microbiota transplantation on chronic fatigue syndrome.
    Salonen T; Jokinen E; Satokari R; Lahtinen P
    J Transl Med; 2023 Jul; 21(1):513. PubMed ID: 37516837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder.
    Chen Y; Xueying Z; Jiaqu C; Qiyi C; Huanlong Q; Ning L; Yasong D; Xiaoxin Z; Rong Y; Jubao L; Xiaoqiong L; Chunlian M; Yu W; Shidong C; Guifang K; Dongmei Z; Shuanfeng F; Xujing Z; Binrang Y; Yanxia W; Ling L; Song Y; Xiang Z; Beihua Z; Lin J; Hong J;
    BMJ Open; 2022 Jan; 12(1):e051613. PubMed ID: 35105621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.